ITGBL1 and breast cancer: When a blocker of the TGF-β SMAD signaling pathway was used, all of the effects of ITGBL1 overexpression were suppressed, suggesting that the TGF-β signaling pathway mediates the role of ITGBL1 in breast cancer bone metastasis.